Skip to main content

Table 1 Demographic and clinical data of the study population

From: Fluorescence optical imaging in pediatric patients with inflammatory and non-inflammatory joint diseases: a comparative study with ultrasonography

  Group I: JIA patients with clinically active arthritis in the hand region Group II: non-inflammatory joint diseases Group III: all JIA patients
  (n = 29) (n = 23) (n = 53)
  n % n % n %
Gender
 Female 23 79 19 83 45 85
 Male 6 21 4 17 8 15
 Age (years), mean (SD); median 13.7 (3.3); 14.0 13.8 (2.4); 14.9 13.7 (3.3); 14.1
 Disease duration (years), mean (SD); median 3.3 (4.0); 1.6 1.7 (1.8); 1.1 3.7 (4.1); 2.1
Diagnosis
 Juvenile idiopathic arthritis 29 100.0 n.a. n.a. 53 100.0
 Systemic arthritis 0 0.0 n.a. n.a. 1 2
 Oligoarthritis, persistent 0 0.0 n.a. n.a. 6 11
 Oligoarthritis, extended 0 0.0 n.a. n.a. 1 2
 Polyarthritis, seronegative 19 66 n.a. n.a. 28 53
 Polyarthritis, seropositive 5 17 n.a. n.a. 7 13
 Enthesitis-related arthritis 2 7 n.a. n.a. 6 11
 Psoriatic arthritis 2 7 n.a. n.a. 3 6
 Other arthritis 1 3 n.a. n.a. 1 2
 Arthralgia n.a. n.a. 23 100 n.a. n.a.
Physician’s global assessment (NRS 0–10)
 Mean (SD) 3.4 (1.9) n.a. 2.4 (1.9)
 Inactive disease (NRS < 1) 0 0.0 n.a n.a. 9 17
Therapy
 Nonsteroidal anti-inflammatory drugs 20 69 10 43.5 31 59
 Systemic glucocorticoids, low dose 5 17 0 0.0 6 11
 Systemic glucocorticoids, high dose 3 10 0 0.0 3 6
 Disease-modifying antirheumatic drugs 19 65 0 0.0 32 60
 Methotrexate 15 52 0 0.0 23 43
 Sulfasalazine 2 7 0 0.0 3 6
 Leflunomide 1 3 0 0.0 1 2
 Etanercept 4 14 0 0.0 6 11
 Adalimumab 0 0.0 0 0.0 3 6
 Abatacept 1 3 0 0.0 1 2
 Tocilizumab 2 7 0 0.0 2 4
 Canakinumab 1 3 0 0.0 1 2
 ESR (mm/h), mean (SD); n 17.0 (19.2); 24 9.5 (6.5); 21 14.8 (16.1); 44
 CRP (mg/dl), mean (SD); n 0.4 (0.5); 28 0.1 (0.1); 23 0.3 (0.5); 48
cJADAS-10
 Mean (SD) 13.3 (4.8) n.a 9.5 (5.9)
 Inactive disease (cJADAS-10 ≤ 1) 0 0.0 n.a. 3 6
CHAQ
 Mean (SD) 0.7 (0.6) 0.5 (0.6) 0.5 (0.6)
 No functional disability (CHAQ = 0) 7 24 8 27 16 30
 Patient’s Global Assessment (NRS 0–10), mean (SD) 2.6 (2.2) 3.9 (3.4) 2.6 (2.2)
  1. JIA juvenile idiopathic arthritis, SD standard deviation, n.a. not applicable, NRS numerical rating scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein, cJADAS clinical Juvenile Arthritis Disease Activity Score, CHAQ Childhood Health Assessment Questionnaire